Taysha Gene Therapies (TSHA) Gains from Sales and Divestitures: 2022-2025
Historic Gains from Sales and Divestitures for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $1.2 million.
- Taysha Gene Therapies' Gains from Sales and Divestitures rose 285.79% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 285.79%. This contributed to the annual value of $323,031 for FY2024, which is 42.00% down from last year.
- As of Q3 2025, Taysha Gene Therapies' Gains from Sales and Divestitures stood at $1.2 million, which was down 0.00% from $1.2 million recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Gains from Sales and Divestitures peaked at $1.2 million during Q2 2025, and registered a low of $17,334 during Q1 2024.
- Moreover, its 3-year median value for Gains from Sales and Divestitures was $474,209 (2023), whereas its average is $571,355.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first plummeted by 93.10% in 2024, then skyrocketed by 5,953.64% in 2025.
- Over the past 4 years, Taysha Gene Therapies' Gains from Sales and Divestitures (Quarterly) stood at $628,921 in 2022, then declined by 11.44% to $556,989 in 2023, then tumbled by 42.00% to $323,031 in 2024, then surged by 285.79% to $1.2 million in 2025.
- Its Gains from Sales and Divestitures was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.0 million in Q1 2025.